孟鲁司特钠片联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的临床研究

发布时间：2018-05-12 05:45

本文选题：孟鲁司特钠片 + 布地奈德福莫特罗粉吸入剂　；参考：《中国临床药理学杂志》2017年24期

【摘要】：目的观察孟鲁司特钠片联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的临床疗效及安全性。方法将120例支气管哮喘患者随机分为对照组60例和试验组60例。对照组予以布地奈德福莫特罗粉吸入剂每次320μg/9μg,bid,经口吸入;试验组在对照组治疗的基础上,予以孟鲁司特钠每次10 mg,qd,睡前口服。2组患者均治疗12周。比较2组患者的临床疗效、肺功能,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为93.33%(56例/60例)和73.33%(44例/60例),差异有统计学意义(P0.01)。治疗后,试验组和对照组的第1秒用力呼气容积分别为(3.05±0.76)和(2.54±0.81)L,用力肺活量分别为(4.34±0.92)和(3.59±0.99)L,呼气峰流速分别为(5.08±1.36)和(3.94±1.22)L,差异均有统计学意义(均P0.01)。2组患者的药物不良反应以恶心口干、眩晕嗜睡和腹泻呕吐为主,试验组和对照组的总药物不良反应发生率分别为30.00%和21.67%,差异无统计学意义(P0.05)。结论孟鲁司特钠片联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的临床疗效确切,其可显著提高患者的肺功能,且不增加药物不良反应的发生率。
[Abstract]:Objective to observe the clinical efficacy and safety of montelukast sodium tablets combined with budesonide formoterol powder inhalation in the treatment of bronchial asthma. Methods 120 patients with bronchial asthma were randomly divided into control group (n = 60) and experimental group (n = 60). The control group was given budesonide formoterol powder inhalation (320 渭 g / 9 渭 g / d), and the experimental group was treated with montelukast sodium 10 mg / kg QD before bedtime for 12 weeks. The clinical efficacy, pulmonary function and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the test group and the control group were 93.3333 / 56 and 73.33 / 44 / 60, respectively. The difference was statistically significant (P 0.01). After treatment, the forced expiratory volume in the test group and the control group were 3.05 卤0.76) and 2.54 卤0.81 L, respectively, the forced vital capacity was 4.34 卤0.92 and 3.59 卤0.99 L, the peak expiratory flow rate was 5.08 卤1.36 and 3.94 卤1.22 L, respectively. The incidence of total adverse drug reactions in the test group and the control group was 30.00% and 21.67, respectively. There was no significant difference between the two groups (P 0.05). Conclusion Montelukast sodium tablet combined with budesonide formoterol powder inhalation is effective in the treatment of bronchial asthma. It can significantly improve the pulmonary function of the patients and does not increase the incidence of adverse drug reactions.
【作者单位】：福建医科大学附属闽东医院呼吸科;福建医科大学附属闽东医院骨科;
【基金】：福建省宁德市科学技术局计划基金资助项目(20140024)
【分类号】：R562.25

【相似文献】